279 related articles for article (PubMed ID: 26206899)
21. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
22. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
[TBL] [Abstract][Full Text] [Related]
24. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
26. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
Dolapcioglu K; Boz A; Baloglu A
Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
[TBL] [Abstract][Full Text] [Related]
28. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
Qi X; Zhao W; Duan Y; Li Y
Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
[TBL] [Abstract][Full Text] [Related]
29. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
30. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
31. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
Gallos ID; Ganesan R; Gupta JK
Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
33. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
34. Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.
Kuzel D; Mara M; Zizka Z; Koliba P; Dundr P; Fanta M
Gynecol Endocrinol; 2019 Feb; 35(2):112-114. PubMed ID: 30449212
[TBL] [Abstract][Full Text] [Related]
35. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
36. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
37. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
van der Meer AC; Hanna LS
Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
[TBL] [Abstract][Full Text] [Related]
38. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
Jiang J; Du H; Peng H
Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
[TBL] [Abstract][Full Text] [Related]
39. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia.
Behnamfar F; Ghahiri A; Tavakoli M
J Res Med Sci; 2014 Aug; 19(8):686-90. PubMed ID: 25422650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
